[ALQA] Alliqua BioMedical, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.6 Change: -0.01 (-1.88%)
Ext. hours: Change: 0 (0%)

chart ALQA

Refresh chart

Strongest Trends Summary For ALQA

ALQA is in the long-term down -96% in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alliqua, Inc., a biomedical company, focuses on the development, manufacture, and distribution of proprietary transdermal wound care and drug delivery technologies. The company provides water content, electron beam cross-linked, and aqueous polymer hydrogels for use in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. Its products include SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. The company also develops HepaMate, an extracorporeal temporary liver support system designed to provide whole liver function to patients with acute or severe liver failure. It has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. Alliqua, Inc. is headquartered in Langhorne, Pennsylvania.

Fundamental Ratios
Shares Outstanding EPS-0.72 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 103.86% Sales Growth - Q/Q27.04% P/E-0.51
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-98.06% ROE-142.18% ROI
Current Ratio3.33 Quick Ratio2.97 Long Term Debt/Equity Debt Ratio0.26
Gross Margin39.02% Operating Margin-385.83% Net Profit Margin-381.53% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities50 K Cash From Investing Activities-10 K Cash From Operating Activities-5.88 M Gross Profit730 K
Net Profit-7.66 M Operating Profit-7.68 M Total Assets24.55 M Total Current Assets14.76 M
Total Current Liabilities4.43 M Total Debt290 K Total Liabilities7.62 M Total Revenue2.11 M
Technical Data
High 52 week2.72 Low 52 week1.63 Last close1.63 Last change-2.4%
RSI41.46 Average true range0.1 Beta0.07 Volume172.59 K
Simple moving average 20 days-4.39% Simple moving average 50 days-18.72% Simple moving average 200 days-22.4%
Performance Data
Performance Week-3.55% Performance Month-7.91% Performance Quart-38.51% Performance Half-20.87%
Performance Year-26.91% Performance Year-to-date-9.94% Volatility daily3.24% Volatility weekly7.24%
Volatility monthly14.83% Volatility yearly51.37% Relative Volume957.42% Average Volume14.74 K
New High New Low

News

2019-01-03 07:00:00 | Alliqua Biomedical CEO Provides Update to Shareholders

2018-12-27 07:35:00 | New Research: Key Drivers of Growth for Zillow Group, Woodward, Navistar International, Multi-Color, Ferrellgas Partners, and Alliqua BioMedical — Factors of Influence, Major Initiatives and Sustained Production

2018-12-14 10:25:00 | What to Watch as Healthcare Stocks Continue to Outperform the Market

2018-11-30 15:28:35 | Trade The Market, Not Your Expectations

2018-11-29 10:10:00 | Healthcare Stocks Following New Market Trends: Premier Health Group PHGRF PHGI, Alliqua BioMedical, Tonix Pharma, & Adial Pharma

2018-11-29 06:50:00 | Today's Research Reports on Trending Tickers: Alliqua BioMedical and Catalyst Pharmaceuticals

2018-11-28 14:19:21 | Cannabis Connection Sends Alliqua Shares Soaring Nearly 200%

2018-11-28 11:50:00 | Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. OTC: PHGRF CSE: PHGI, Alliqua BioMedical, BioScrip, Coremedix

2018-11-28 07:30:00 | Alliqua BioMedical to spin off and merge its Contract Manufacturing Business with TO Pharmaceuticals LLC to Create an Independent, Publicly Traded Company focused on Cannabinoid-Based Pharmaceutical Therapies

2018-10-29 09:00:00 | Consolidated Research: 2018 Summary Expectations for Green Brick Partners, Alliqua BioMedical, Buckle, DaVita, CDK Global, and Mylan N.V — Fundamental Analysis, Key Performance Indications

2018-10-15 17:06:55 | Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners

2018-10-12 07:00:00 | Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation

2018-09-28 08:20:00 | New Research Coverage Highlights Employers, Alliqua BioMedical, Express Scripts Holding, CF Industries, Nutanix, and Coca-Cola — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-09-14 10:49:06 | How Does Investing In Alliqua BioMedical Inc NASDAQ:ALQA Impact Your Portfolio?

2018-06-27 09:30:29 | Is There Now An Opportunity In Alliqua BioMedical Inc NASDAQ:ALQA?

2018-06-11 08:00:00 | Investor Expectations to Drive Momentum within Gorman-Rupp, Mistras Group, Inovalon, Johnson Controls International plc, Best Buy Co., and Alliqua BioMedical — Discovering Underlying Factors of Influence

2018-05-07 16:15:00 | Alliqua BioMedical, Inc. Announces Closing Asset Sale to Celularity Inc.

2018-05-01 13:46:15 | Want To Invest In Alliqua BioMedical Inc NASDAQ:ALQA? Here’s How It Performed Lately

2018-03-31 16:39:23 | Are Alliqua BioMedical Inc’s NASDAQ:ALQA Interest Costs Too High?

2018-03-22 10:38:10 | Should You Buy Alliqua BioMedical Inc NASDAQ:ALQA At $1.84?

2018-03-13 17:32:00 | Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Alliqua Biomedical, Inc. In The District Of Delaware

2018-02-01 17:47:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Alliqua BioMedical, Inc. - ALQA

2018-01-31 07:40:00 | Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-01-09 07:30:00 | Wired News – Alliqua BioMedical Enters into Purchase Agreement with Celularity; Agrees to Sell its Advanced Biologic Wound Care Business

2018-01-05 16:30:00 | Alliqua BioMedical, Inc. Announces Definitive Asset Purchase Agreement with Celularity, Inc.

2017-12-07 07:10:00 | Wired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology

2017-12-01 08:33:12 | Alliqua BioMedical, Inc. :ALQA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017

2017-11-09 18:38:33 | Edited Transcript of ALQA earnings conference call or presentation 9-Nov-17 1:00pm GMT

2017-11-09 07:55:30 | Alliqua reports 3Q loss

2017-11-09 07:02:00 | Alliqua BioMedical, Inc. Reports Third Quarter of Fiscal Year 2017 Financial Results and Increases Fiscal Year 2017 Financial Outlook

2017-11-09 07:01:00 | Alliqua BioMedical, Inc. Engages Cowen to Assist in Evaluating Potential Strategic Alternatives

2017-11-09 06:00:00 | Alliqua, Inc. to Host Earnings Call

2017-10-30 16:05:00 | Alliqua BioMedical, Inc. to Announce Third Quarter of Fiscal Year 2017 Results on November 9th

2017-10-17 19:31:19 | Is It Time To Buy Alliqua BioMedical Inc ALQA?

2017-10-05 16:01:00 | Alliqua BioMedical, Inc. Announces 1-for-10 Reverse Stock Split

2017-09-21 18:15:09 | Have Investors Already Priced In Alliqua BioMedical Inc’s ALQA Growth?

2017-09-11 07:40:00 | Featured Company News - Pfizer Receives Warning Letter from FDA Highlighting Manufacturing Defects in the EpiPen Administered for Anaphylaxis

2017-09-05 19:50:19 | ETFs with exposure to Alliqua BioMedical, Inc. : September 5, 2017

2017-09-05 18:25:11 | [$$] The Add-On Deal Roundup: Sept. 5

2017-09-05 07:30:00 | Alliqua BioMedical, Inc. Announces the Sale of TheraBond® 3D Antimicrobial Barrier Systems Product Line; Alliqua Updates Fiscal Year Outlook

2017-08-25 11:22:49 | Alliqua BioMedical, Inc. :ALQA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

2017-08-10 23:54:59 | Alliqua reports 2Q loss

2017-08-10 18:47:42 | Edited Transcript of ALQA earnings conference call or presentation 10-Aug-17 12:00pm GMT

2017-08-10 07:00:00 | Alliqua BioMedical, Inc. Reports Second Quarter of Fiscal Year 2017 Financial Results

2017-07-26 07:30:00 | Alliqua BioMedical, Inc. to Announce Second Quarter of Fiscal Year 2017 Results on August 10th

2017-06-22 06:54:00 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Alliqua BioMedical, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

2017-06-19 07:30:00 | Alliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to Provide UltraMIST® Customers with New Equipment Financing Programs

2017-06-06 11:36:30 | ETFs with exposure to Alliqua BioMedical, Inc. : June 6, 2017

2017-05-26 12:57:23 | ETFs with exposure to Alliqua BioMedical, Inc. : May 26, 2017

2017-05-15 15:12:34 | ETFs with exposure to Alliqua BioMedical, Inc. : May 15, 2017